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Matrix metalloproteinase (MMP) overexpression has been implicated in the pathogenesis of colorectal carcinoma (CRC).
Accumulating evidence suggests that MMP promoter single nucleotide polymorphisms (SNPs) effecting gene transcription are
associated with enhanced susceptibility for the development of malignant disease, increased tumour invasiveness and poor patient
survival. The aim of the current investigation was to determine whether such associations exist in a large CRC patient/control study
population. Using an allelic discrimination real-time polymerase chain reaction, polymorphisms in the MMP-1, MMP-2 and MMP-3
gene promoters ( 1607,  1306, and  1612bp, respectively) were assessed in normal blood mononuclear cells from patients with
CRC (n¼503) and control subjects (n¼471). Genotypes corresponding to each MMP SNP were correlated with tumour
characteristics and clinical outcome. The frequency of each genotype was not statistically different between patients and control
subjects and no significant differences were noted between the genotypes and tumour characteristics for the three MMP SNPs. CRC
patients with the 2G/2G genotype for the MMP-1 SNP had significantly better 5-year survival compared to patients with a 1G allele
(Po0.05). Our results demonstrate that CRC patients with a 2G/2G genotype in the MMP-1 gene promoter SNP have a favourable
prognosis. Although our results were unexpected, given that this genotype is associated with enhanced MMP-1 transcriptional activity,
they are consistent with recent data highlighting the anti-tumorigenic properties of MMPs.
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Colorectal carcinoma (CRC) is one of the most common
malignancies in the western world. Despite advances in surgical
techniques, improved chemotherapy, and early detection, this
malignancy is still associated with a relatively poor prognosis and
at least 40% of patients who undergo resection of the primary
tumour die within 5 years either because of local recurrence or
metastatic disease (Midgley and Kerr, 1999). Currently, the most
clinically useful prognostic indicator in CRC is tumour stage, as
determined by the extent of local tumour invasion and metastatic
spread. Degradation of extracellular matrix is required for tumour
cell migration and dissemination, a process that is facilitated by a
family of neutral proteolytic enzymes known as the matrix
metalloproteinases (MMPs) (Wagenaar-Miller et al, 2004). Given
their critical role in cancer, attempts have been made to design
synthetic MMP inhibitors (MMPI) in the hope of limiting
metastatic spread. Results from clinical trials using MMPIs have
been disappointing, predominantly because of severe side effects
as well as the lack of tumour responsiveness to these agents
(Coussens et al, 2002).
Matrix metalloproteinases are a family of calcium- and zinc-
dependent endopeptidases that share amino-acid sequences,
structural domains, and overlapping substrates. These enzymes
are secreted as zymogens and removal of an activation peptide is
required for their proteolytic activity (Nagase and Murphy, 2004).
Matrix metalloproteinases maintain and remodel tissue architec-
ture under normal physiological and pathological conditions
(Nagase and Murphy, 2004). They are broadly divided into the
collagenases, gelatinases, stromelysins, and membrane-associated-
MMPs on the basis of their substrate specificity. Overexpression of
MMP-1 (Murray et al, 1996), MMP-2 (Papadopoulou et al, 2001),
and MMP-3 (Roeb et al, 2004) has been linked to poor prognosis,
high tumour stage, and enhanced tumour invasiveness in patients
with CRC. These subjective and semiquantitative studies have
inspired subsequent investigators to assess genetic polymorphisms
in the promoter regions of MMP genes, as this type of DNA
sequence alteration can affect cancer susceptibility and malignant
phenotype (Yasui et al, 2005).
In relation to tumour progression, MMP-1 has received
relatively little attention compared to the basement membrane-
degrading proteinases (MMP-2, -9). The promoter region of the
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proteins such as AP-1, AP-2, Ets/PEA-3, and responsive elements
to glucocorticoids, retinoic acid, and cyclic AMP (Rutter et al,
1997). A single nucleotide polymorphism (SNP) has been
identified at position  1607bp within the MMP-1 promoter
region, whereby the insertion of an additional guanine (G) residue
creates an extra Ets-binding site (Rutter et al, 1998). A promoter
containing this SNP (giving rise to the 2G genotype) displays
significantly ‘higher’ transcriptional activity in normal and
malignant cells compared to cells possessing a 1G allele (Rutter
et al, 1998; Wyatt et al, 2002) with ‘lower’ transcriptional activity.
Several studies have identified strong linkage between this
polymorphism and several common malignancies, including
colorectal (Ghilardi et al, 2001; Hinoda et al, 2002; Zinzindohoue
et al, 2005; Elander et al, 2006), endometrial (Nishioka et al, 2000),
lung (Zhu et al, 2001), and ovarian (Kanamori et al, 1999) cancers
and melanoma (Rutter et al, 1998; Tower et al, 2002). Polymorph-
isms in the promoter of MMP-2 (Miao et al, 2003), MMP-3
(Ghilardi et al, 2002), and MMP-7 (Zhang et al, 2005) have also
been associated with increased susceptibility to the development of
cancer, and to poorer prognosis, but these associations have not
been found in all studies (Lei et al, 2002; Wenham et al, 2003; Fong
et al, 2004; Krippl et al, 2004; Zinzindohoue et al, 2005).
We undertook the current investigation to determine whether an
association could be found between the MMP-1, -2, and -3 gene
promoter SNPs and CRC using the largest patient/control cohort to
date. A reliable, rapid, non-radioactive real-time PCR method was
developed to enable high sample throughput. Our results
demonstrate that of the SNPs studied, none were associated with
increased susceptibility to developing CRC, nor was there a
significant correlation with any tumour characteristic analysed.
Surprisingly, and contrary to other reports, we found that patients
with CRC carrying the MMP-1 2G SNP had significantly improved
5-year survival. These findings may be of significance given the
recent development and clinical trialing of MMP inhibitors.
MATERIALS AND METHODS
Study subjects
This study included 503 CRC patients without synchronous
metastases who had undergone curative resection at St Vincent’s
Hospital, Sydney (Table 1). Enrolment of CRC patients in the study
was between 1 January 1994 and 29 May 2004, and patient follow-
up was performed for a period of up to 5 years or until death.
Cancer recurrence dates and causes of death were obtained from
medical records and death certificates where appropriate. Follow-
ing informed consent, peripheral blood samples were obtained
from all patients. This aspect of the study was approved by the St
Vincent’s Hospital Human Research Ethics Committee. Histologi-
cal analysis of the tumours has been described previously (Ward
et al, 2003). Peripheral blood from 471 healthy controls was
obtained from volunteer donors at the Red Cross Blood Bank,
Sydney, over a 3-week period after they provided informed consent
for their DNA to be used anonymously for research into genetic
predisposition to CRC. This aspect of the study was approved by
the Red Cross Blood Bank Human Ethics Committee. For
nucleotide sequencing, genomic DNA (gDNA) was extracted from
peripheral blood mononuclear cells and amplified by PCR and
real-time PCR using standard methods. Tumour-derived gDNA
was randomly selected from 61 CRC patients known to be
heterozygous for the MMP-1 polymorphism and used to study
loss of heterzygosity (LOH).
The clinical staging of all tumours was completed according to
AJCC/UICC guidelines. The anatomical location of the tumour was
categorised into two groups: right-sided (proximal to and
including the splenic flexure) or left-sided (descending colon,
sigmoid, or rectum). Tumour margin type was established as
described by Jass et al (1987); circumscribed when the margin was
pushing or reasonably well circumscribed, or as infiltrating when
the tumour invades in a diffuse manner with widespread
penetration of normal tissues. The level of mucin production
was determined as positive if present in 450% of the tumour area.
Intra-epithelial lymphocytes were classified as inconspicuous
(p20mm
 2) or prominent (420mm
 2).
Amplification of DNA for nucleotide sequencing
Polymerase chain reaction (PCR) was carried out on gDNA using
specific forward and reverse primer pairs (Sigma Genosys,
Australia) designed to span the MMP-1 (50-TTATGCCACTTA
GATGAGGAAATTGT-30 and 50-CACTTTCCTCCCCTTATGGAT
TC-30), MMP-2 (50-TCTGGGCCATTGTCAATGTTC-30 and 50-TC
AAGGAAGGCTTCCTGGAA-30) and MMP-3 (50-CGGCACCTGGC
CTAAAGAC-30 and 50-TCCTCATATCAATGTGGCCAAA-30) poly-
morphic sites to generate PCR products of 151/ 152, 117, and 127/
128, respectively. Reactions were carried out in a final volume of
25ml, containing 50ng of gDNA, 15pmol of each primer, 10mM of
each dNTP, 20mM Tris–HCl (pH 8.4), 50mM KCl, 1mM MgCl2 and
1U Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA,
USA). Thermal cycling was performed in a GeneAmp PCR System
2400 thermal cycler (Perkin Elmer, Foster City, CA, USA) using the
following conditions: 951C for 1min, followed by 30 cycles of
amplification (951C denaturation for 30s, 551C annealing for 30s,
721C extension for 30s), and a final extension at 721C for 5min.
Amplified products were separated on a 2% agarose gel, stained
with 5–10mgml
 1 ethidium bromide and visualised under UV
light. PCR products were gel-purified using the Wizard SV Gel and
PCR Clean-Up System kit (Promega Co, Madison, WI, USA) and
their nucleotide sequence determined by a commercial sequencing
Table 1 Demographic characteristics and distribution of the MMP-1,
MMP-2, and MMP-3 SNPs in CRC patients
Groups Patients n (%)
Sex
Male 265 (52.7)
Female 238 (47.3)
Tumour stage
I 36 (7.2)
II 94 (18.7)
III 286 (58.9)
IV 87 (17.3)
Average age (years)
Male 66.9
Female 70.5
Mean age in years (s.d.) 68.6 (12.1)
MMP-1 SNP allelotype
1G 500 (51.0)
2G 480 (49.0)
MMP-2 SNP allelotype
C 735 (75.6)
T 237 (24.4)
MMP-3 SNP allelotype
5A 443 (47.1)
6A 497 (52.9)
Abbreviations: CRC, colorectal carcinoma; MMP, matrix metalloproteinase; SNP,
single nucleotide polymorphisms.
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sfacility (Sydney University and Prince Alfred Molecular Analysis
Centre (SUPAMAC)).
Real-time PCR allelic discrimination analysis
Matrix metalloproteinase-1, MMP-2 and MMP-3 gene promoter
SNPs were analysed by a real-time PCR allelic discrimination
TaqMan assay (Applied Biosystems Inc., Foster City, CA, USA) on
an ABI Prism 7700 Sequence Detection System (Applied Biosys-
tems Inc.). The primers and TaqMan minor groove binding (MGB)
probes for the MMP-1 (1G allele 6FAM-AGTTAAATAATTA
GAAAGATATGACTTATC-NFQ and 2G allele VIC-AGTTAAA
TAATTAGAAAGGATATGACTTATC-NFQ), MMP-2 (C allele
6FAM-AGCACTCCACCTCTTTAGCT-NFQ and T allele VIC-AG
CACTCTACCTCTTTAGCT-NFQ) and MMP-3 (5A allele 6FAM-
GGGAAAAACCATGTCTTGT-NFQ and 6A allele VIC-
GGGAAAAAACCATGTCTTGT-NFQ) were designed using Primer
Express v2.0 software (Applied Biosystems Inc.), and the MGB
probes were synthesised by Applied Biosystems Inc. Primer
specificity was examined under standard PCR conditions before
use in the allelic discrimination assay. Reactions were run in
duplicate with the appropriate no template (NTC) and/or no
amplification (NAC) controls. Each reaction consisted of 1 
Rainbow Probe Master Mix (Quantace Ltd, Watford, UK),
500nmoll
 1 each primer, 100nmoll
 1 each TaqMan MGB probe
and 50ng template in a final volume of 20ml. Thermal cycler
conditions were, 501C for 2min, 951C for 10min followed by 35
cycles of 921C for 15s and 601C for 1min. All real-time PCRs were
monitored and analysed using the Sequence Detector v1.7 software
(Applied Biosystems Inc.).
Immunohistochemical analysis of tissue microarrays
Paraffin-embedded CRC blocks were obtained from St Vincent’s
Hospital, Sydney. Haematoxylin and eosin stained slides from all
cases were reviewed and the tumour tissue was selected and
marked. Tissue micro arrays (TMAs) containing two 1-mm-
diameter cores from each tumour were constructed using a manual
arrayer (Beecher Instruments, Silver Spring, MD, USA). From each
of the resulting 12 arrays, 4mm sections were immunostained with
an MMP-1 monoclonal antibody (Calbiochem, Darmstadt,
Germany, clone 41–1E5) at a 1:600 dilution for 30min on a Bond
Xt automated immunostainer (Vision BioSystems, Melbourne,
Australia) using a Polymer Defined Detection System, Vision
Biosystems, Melbourne, Australia. Sections were counterstained
with haematoxylin and a staining index developed to report the
intensity of MMP-1 positivity within the epithelial component of
the TMA, with 3þ equivalent to high, 2þ indicating medium, 1þ
corresponding to low, and 0 indicating absence of MMP-1 staining.
Interestingly, MMP-1 staining was either present or absent within
the stromal component of diseased tissue and was scored
appropriately. The immunostained TMAs were reviewed by three
independent observers who were masked to the MMP-1 genotype
of each patient. Discordant observations were resolved by attaining
consensus, and when this could not be achieved, the core was
omitted from the analysis (n¼11, B3%). Negative controls
include sections incubated without a primary antibody or in the
presence of an isotype-matched control antibody for which no
reactivity was observed.
Statistical analyses
Statistical analyses were performed using SPSS 13.0. software
package for Windows (SPSS Inc., Chicago, IL, USA). The w
2 test
was used to compare differences in categorical variables between
the CRC patients and the control group, as well as within the CRC
patient group for each of the MMP SNP sites. Cox regression
analysis was used to calculate the odds ratio (OR) and 95%
confidence interval (CI) to test the association between MMP
promoter genotype and the risk of CRC. Survival times were
measured from the date of resection to the date of death, and cases
were censored at the completion of 5 years of follow-up, or at the
last clinical visit before 30 June 2005. Non-cancer-related deaths
were censored at the date of death. The log rank test was used to
test the statistical difference between Kaplan–Meier survival
curves (Kaplan and Meier, 1958). The threshold for significance
was Po0.05.
RESULTS
Patient demographics and MMP allelotype distribution
The study population (Table 1) consisted of 503 patients with CRC
(265 (52.4%) males and 238 (47.3%) females) with an age range of
28.6–99 years, as well as 471 control subjects with an age range of
17.6–78.6 (281 (59.7%) males and 190 (40.3%) females). Patients
and control subjects were derived from the same geographic
location and are representative of an Australian population. The
gender distribution between patients and control subjects was not
statistically significant (P¼0.13). The genotype distribution for
MMP-1 (1G and 2G) did not deviate significantly (P¼0.78)
between patients with CRC (51.0 and 49.0%, respectively) and
controls (50.4 and 49.6%, respectively). In addition, there was no
significant difference recorded between patients and controls for
the MMP-2 (P¼0.61) or the MMP-3 (P¼0.21) allelotype
frequencies (data not shown).
Matrix metalloproteinase genotype distribution and
susceptibility to CRC
Each MMP gene promoter SNP was determined by an allelic
discrimination real-time PCR assay. Typical dot plots were
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Figure 1 Matrix metalloproteinase-1 allelic discrimination assay plot. A representative genotype assay plot to demonstrate segregation of the three
possible genotypes generated for MMP-1 SNP (circle A, 1G/1G homozygotes; circle B, 1G/2G heterozygotes; circle C, 2G/2G homozygotes) based on
fluorescence intensity (x axis, VIC fluorescence; y axis, FAM fluorescence) of each PCR product. For quality control reassurance, sequenced samples for each
genotype were amplified in each assay run along with no template controls (black squares, bottom left corner of plot) for which no products formed. Similar
plots were generated for the MMP-2 and MMP-3 gene promoter SNP (data not shown).
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2 and MMP-3 (data not shown) promoter polymorphisms in our
study population. Patients and control subjects were segregated
according to genotype (Figure 1: A 1G/1G (1G homozygous); B,
1G/2G (heterozygous); C, 2G/2G (2G homozygous) based on
fluorescence intensity. Each assay was calibrated by incorporating
control gDNA from subjects that had sequence proven poly-
morphisms of the MMP-1, -2, -3 promoters. Furthermore, the
allelic discrimination PCR assay was validated by sequencing 90
patients with CRC (10 patients of each genotype (7.5% of the total
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Figure 2 Distribution of the MMP-1, -2, and -3 gene promoter polymorphism in the study population. Genotype frequency for each MMP promoter
polymorphism was established from the allelic discrimination PCR-based assay. Each genotype is expressed as a percentage of the total number of patients
(black bars) or control subjects (white bars). No significant deviation in the distribution of each genotype for any of the three MMP polymorphisms was
noted between patients with CRC compared to control subjects.
Table 2 Patient data and clinicopathological characteristics of tumours according to MMP-1, -2, or -3 promoter SNP genotype
MMP-1 MMP-2 MMP-3
High (2G/2G) High (C/C) High (5A/5A)
vs vs vs
n (%)
a Low (1G/2G + 1G/1G) n (%)
a Low (C/T + T/T) n (%)
a Low (5A/6A + 6A/6A)
Sex 490 (100) 0.43 486 (100) 0.06 470 (100) 0.22
Male 257 (52.4) 257 (52.9) 248 (52.8)
Female 233 (47.6) 229 (47.1) 222 (47.2)
Tumuor location 488 (99.6) 0.49 484 (99.6) 0.67 468 (99.6) 0.37
Left sided 308 (62.8) 309 (63.6) 301 (64.1)
Right sided 180 (36.8) 175 (36.0) 167 (35.5)
Margin type 474 (96.7) 0.54 472 (97.1) 0.13 459 (97.7) 0.86
Circumscribed 365 (74.5) 365 (75.1) 355 (75.5)
Infiltrative 109 (22.2) 107 (22.0) 104 (22.2)
Grade 490 (100) 0.71 486 (100) 0.81 470 (100) 0.46
High 66 (13.5) 64 (13.2) 60 (12.8)
Low 424 (86.5) 422 (86.8) 410 (87.2)
Tumuor stage 490 (100) 0.81 486 (100) 0.61 470 (100) 0.35
I 35 (7.1) 35 (7.2) 32 (6.8)
II 91 (18.6) 91 (18.7) 86 (18.3)
III 278 (56.7) 277 (57.0) 271 (57.7)
IV 86 (17.6) 83 (17.1) 81 (17.2)
Lymph nodes mets 490 (100) 0.20 486 (100) 0.89 470 (100) 0.57
Absent 310 (63.3) 306 (63.0) 300 (63.8)
Present 180 (36.7) 180 (37.0) 170 (36.2)
Mucinous phenotype 489 (99.8) 0.24 485 (99.8) 0.49 469 (99.8) 0.77
Absent 104 (21.2) 106 (21.8) 100 (21.3)
Present 385 (78.6) 379 (78.0) 369 (78.5)
Lymphatic invasion 479 (97.7) 0.78 475 (97.7) 0.95 460 (97.9) 0.91
Absent 373 (76.1) 368 (75.7) 356 (75.7)
Present 106 (21.6) 107 (22.0) 104 (22.2)
Vascular invasion 471 (96.1) 0.55 467 (96.1) 0.16 452 (96.2) 0.99
Absent 381 (77.8) 377 (77.6) 370 (78.7)
Present 90 (18.3) 90 (18.5) 82 (17.5)
Intra-epithelial lymphocytes 488 (99.6) 0.46 484 (99.6) 0.65 468 (99.6) 0.87
Inconspicuous 384 (78.4) 380 (78.2) 366 (77.9)
Prominent 104 (21.2) 104 (21.4) 102 (21.7)
aPercentage expressed as total of genotyped patients within each SNP group studied.
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results showed 100% concordance (data not shown). The MMP-1, -
2, and -3 promoter genotypes were successfully determined for 490
(97.4%), 486 (96.6%), and 470 (93.4%) of the CRC patients and 470
(99.9%), 467 (99.1%), and 452 (96.0%) of the control subjects,
respectively. There was no significant difference in the genotype
distribution (P40.05) for the three MMP SNPs examined between
patients and controls (Figure 2). The discrepancy between the
number of subjects enrolled in the study and the actual number
genotyped reflected failure to generate a sequence profile for some
subjects. It is likely that a PCR inhibiting contaminant within the
failed gDNA samples resulted in our inability to obtain a genotype
call from either the real time assay or from sequence analysis. In
any case, this failure rate was o3% in both CRC cases and controls
for the MMP-1 SNP.
Matrix metalloproteinase genotype and clinical phenotype
Potential associations were explored between MMP genotype and
phenotypic tumour characteristics such as tumour stage, differ-
entiation, TMN resection status, mucinous phenotype, lymphatic,
vascular, or perineural invasion. No significant differences were
detected between these and other tumour characteristics and MMP
genotypes, irrespective of whether the analysis was performed as
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Figure 3 Kaplan–Meier curves for overall survival stratified by MMP promoter genotype. Survival curves for the MMP-1 (A and B), MMP-2 (C and D),
and MMP-3 (E and F) gene promoter polymorphisms were generated based on individual genotype (A, C, E) or grouped on the basis of high MMP
expression (one genotype) compared to low MMP expression (two genotypes) (B, D, F). No significant difference in survival was noted for the MMP-2 or
MMP-3 SNP, irrespective of the method of analysis (P40.05). However, patients homozygous for the 2G allele in the MMP-1 promoter (one genotype
analysis) had a favourable prognosis (P¼0.031) when compared to patients with a 1G allele (A). When the genotypes associated with low MMP-1
expression (1G/1G and 1G/2G) were combined and compared to high MMP-1 expression (2G/2G), patient survival was further enhanced (P¼0.019).
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Table 2) or ‘low’ vs ‘high’ (viz., 1G/1G genotype vs both 1G/2G and
2G/2G) MMP-1 expression (data not shown).
Matrix metalloproteinase genotype and survival analysis
Correlation between the MMP-1, -2, and -3 genotypes and survival
was analysed and plotted using Kaplan–Meier survival curves
(Figure 3). Patient survival was analysed on the basis of a single
genotype or stratified according to ‘high’ MMP expression (one
genotype) compared to ‘low’ MMP expression (two genotypes).
Patients homozygous for the MMP-1 1G allele exhibited signifi-
cantly poorer survival compared to those carrying a 2G allele
(P¼0.031). The Kaplan–Meier curves generated for this poly-
morphism demonstrated a pattern suggestive of a dose–response
effect (Figure 3A). Likewise, when the MMP-1 genotypes were
analysed according to ‘high’ (2G/2G) compared to ‘low’ (1G/1G
plus 1G/2G) MMP-1 expression, patients homozygous for the 2G
allele had significantly improved survival rates (P¼0.019)
(Figure 3B). In contrast, no significant association was found
between the MMP-2 and MMP-3 genotypes and survival in
patients, irrespective of the genotype grouping utilised, for
example as a single genotype (Figure 3C and 3E) or a ‘high’
(C/C) vs combined ‘low’ (C/T and T/T) MMP-2 expression
(Figure 3D), or ‘high’ (5A/5A) vs combined ‘low’ (5A/6A and
6A/6A) MMP-3 expression (Figure 3F).
Multivariate analysis
A multivariate analysis (Cox regression) was performed for each
polymorphism using two different genotype groupings (Table 3). It
was found that the OR of CRC-associated death for the MMP-1
2G/2G homozygous genotype compared with the 1G/2G and 1G/1G
genotypes was 0.427 (95% CI 0.19–0.96, P¼0.04). The distribution
of the other genotypes relating to MMP-2 and MMP-3 showed no
significant difference (OR 1.16; 95% CI 0.66–2.04, OR 1.59; 95% CI
0.87–2.84, respectively) with respect to CRC-related death
(Table 3).
Immunohistochemical analysis of TMAs
Three distinct patterns of MMP-1 expression (high, medium, and
low) were apparent in the tumour epithelium (n¼363; Figure 4A–
C respectively), whereas two patterns of MMP-1 expression
(positive and negative) were displayed by the stromal component
(n¼402; Figure 4D and E, respectively). No significant association
was found between MMP-1 genotype and MMP-1 protein
expression either in the tumour (Figure 4G) or in the stromal
component (Figure 4I). Interestingly, the presence of MMP-1
within tumour stroma was associated with increased overall
survival (log rank test, P¼0.044, Figure 4J), however no significant
survival advantage was observed when MMP-1 protein was
assessed in the tumour (log rank test, P¼0.331, Figure 4H).
Although this data is independent of MMP-1 genotype, it supports
the notion that MMP-1 overexpression is indeed associated with
favourable prognosis in our patient cohort.
Loss of heterozygozity
Loss of heterozygosity (LOH) has been described at the MMP-1 -
1607/2G polymorphic site in malignant melanoma (Noll et al,
2001). Our results showed no obvious LOH between the gDNA
compared to the tumour-derived DNA in 100% of the randomly
selected samples (n¼61; data not shown) and this was comparable
to other studies in renal (Hirata et al, 2003) and endometrial
(Nishioka et al, 2000) carcinomas.
DISCUSSION
In this report, we describe a PCR-based allelic discrimination assay
for the MMP-1, -2, and -3 gene promoter polymorphisms. This is
an accurate and reproducible screening tool, and along with an
improved throughput capacity compared to previously published
methods, may be the technique of choice for the rapid screening of
large numbers of DNA samples. Although previous studies have
documented a strong association between the 2G polymorphism in
the MMP-1 promoter and the occurrence of several common
cancers, including CRC, we were unable to corroborate these
findings. At the same time, by using the largest patient/control
cohort to date, and a robust and reliable PCR-based assay, we have
shown that the 2G polymorphism in the MMP-1 promoter was a
favourable prognostic indicator in patients with CRC as measured
by a 5-year survival.
Several reports have demonstrated an association between MMP
overexpression and poor prognosis in patients with cancer. For
example, shorter disease-free survival was noted in patients with
oral squamous cell carcinoma (SCC) expressing higher MMP-2
enzymatic activity (Yorioka et al, 2002). Matrix metalloproteinase-
1 reactivity was found to be associated with poor outcome in
patients with oesophageal (Murray et al, 1998) and CRC (Murray
et al, 1996), whereas MMP-9 immunoreactivity correlated with a
markedly poorer outcome in patients with SCC of the head and
neck (5-year cause specific survival of 45% in MMP-9-positive
tumours vs 92% in MMP-9 negative cases) (Ruokolainen et al,
2004). Matrix metalloproteinase-7 positively correlated with depth
of invasion, lymph node metastasis, lymphatic invasion, tumour
stage, and poorer outcome in patients with CRC (Adachi et al,
2001). Similarly, abundant MMP-11 (Chenard et al, 1996) and
MMP-2 (Talvensaari-Mattila et al, 2003) immunoreactivity in
tissue from patients with breast cancer corresponded to a shorter
disease-free survival and poorer overall survival.
Despite this literature linking enhanced MMP production with
poorer outcome for patients with cancer, the majority of these
studies have been at best semi-quantitative and are a measure of
expression at a single time point over the course of malignant
progression (Chenard et al, 1996; Murray et al, 1996, 1998; Adachi
et al, 2001; Papadopoulou et al, 2001; Yorioka et al, 2002;
Talvensaari-Mattila et al, 2003; Roeb et al, 2004; Ruokolainen et al,
2004). The discovery of polymorphisms in MMP promoters that
alter gene expression has revealed strong associations between
these genetic variants and increased susceptibility to the develop-
ment of malignancies and other diseases (Henney et al, 2000; Ye,
2000). The most extensively studied MMP SNP in relation to
Table 3 Association of tumour characteristics and the MMP-1, MMP-2
and MMP-3 SNPs with CRC-associated death
OR 95% CI P
Tumour stage 5.96 4.20–8.50 o0.01
Vascular invasion 0.36 0.23–0.60 o0.01
Margin type 0.67 0.43–1.05 0.08
MMP-1
2G/2G vs 1G/2G+1G/1G 0.43 0.19–0.96 0.04
1G/1G vs 1G/2G+2G/2G 1.72 0.95–3.14 0.08
MMP-2
C/C vs C/T+T/T 1.16 0.66–2.04 0.60
T/T vs C/T+C/C 0.67 0.16–2.74 0.57
MMP-3
5A/5A vs 5A/6A+6A/6A 1.59 0.87–2.84 0.12
6A/6A vs 5A/6A+5A/5A 1.17 0.63–2.17 0.62
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(Rutter et al, 1998; Nishioka et al, 2000; Ghilardi et al, 2001; Zhu
et al, 2001; Hinoda et al, 2002; Tower et al, 2002; Wyatt et al, 2002;
Zinzindohoue et al, 2005; Elander et al, 2006). Similar studies have
been conducted for the MMP-2 (Miao et al, 2003) and MMP-3
(Ghilardi et al, 2002; Hinoda et al, 2002) gene promoter
polymorphism in relation to disease susceptibility and metastatic
behaviour. These data suggest that functional polymorphisms,
particularly those that influence high MMP expression, may act as
susceptibility factors for cancer.
Despite the large number of studies that have found clear
associations between MMP SNPs and susceptibility to malignant
disease, some recent reports do not support these findings. Using a
large cohort of patients with breast cancer, Krippl and colleagues
(Krippl et al, 2004) demonstrated that the MMP-3 promoter
polymorphism did not influence disease susceptibility. These
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Figure 4 Immunohistochemical and survival analysis of MMP-1 from tissue microarrays. Immunohistochemical staining for MMP-1 in the epithelial tumour
component demonstrated (A) high, (B) medium, and (C) low-level expression, whereas MMP-1 protein was either (D) present or (E) absent in the stromal
component, (F) negative control incubated with no primary antibody. Distribution of MMP-1 expression as assessed by TMA G: MMP-1 tumour cell
expression levels (low – white bars, medium – grey bars, high – black bars) was expressed as a percentage of the total number of patients in each genotype
group. No significant difference was noted (P¼0.633) in the distribution of MMP-1 protein expression as determined by TMA within each genotype group
(H) Survival curves for MMP-1 expression within the epithelial cells of tumour tissue. No significant difference (P¼0.331) was noted between the different
MMP-1 protein levels. (I) Stromal MMP-1 expression (negative – white bars, positive – black bars) expressed as a percentage of the total number of patients
in each group. There was no significant deviation (P¼0.778) in the distribution of MMP-1 genotype based on stromal MMP-1 expression levels, (J) Survival
curves for stromal MMP-1 expression. Positive immunostaining for stromal MMP-1 was associated with significantly better survival (P¼0.044) compared to
negative reactivity for stromal MMP-1.
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sresults were subsequently confirmed in a smaller study using a
different technique to establish subject genotype (Lei et al, 2002).
The results of our investigation are consistent with these findings,
in that we also were unable to demonstrate differences in the
frequency of the MMP-1, -2, or -3 promoter SNP genotype between
control subjects and patients with CRC. These findings suggest that
analysis of these particular polymorphisms may not be useful
indicators of the risk of developing cancer. As in the current
investigation, other studies have found no significant differences
in allele frequency for the MMP-1 promoter SNP in patients with
colorectal (Biondi et al, 2000) or ovarian (Wenham et al, 2003)
cancer compared to controls. These discordant results may be a
consequence of the accuracy of the different techniques used to
sequence these polymorphic sites, the source of DNA (tumour-
derived compared to normal genomic), the number of subjects or
the ethnicity of the population (Lai et al, 2005).
Despite the absence of a direct correlation between the MMP-1
2G polymorphism (associated with high MMP-1 protein expres-
sion) and MMP-1 staining in the tumour tissue, this comes as no
surprise as MMP-1 tissue expression may be influenced by host
immune response, disease stage, therapy, etc. Moreover, the
immunohistochemical technique we employed may not be the
method of choice to identify such an association, as it represents
only a single period in tumour evolution. Our TMA results also
highlight the potentially important contribution of MMP-1
production by stromal cells and indicate that tumour/stromal
interactions may play a critical role in modulating gene expression
to effect prognosis in patients with CRC (Kim et al, 2005). In the
context of MMP function related to tumour progression, it has
been speculated that enhanced MMP expression facilitates tumour
cell invasion and metastasis, ultimately resulting in poor
prognosis. Interestingly, as well as cancer promoting properties,
cancer-inhibiting attributes have been recently documented for
several MMPs. Indeed increased MMP-9 expression has been
shown to favour survival in node-negative patients with breast
cancer (Scorilas et al, 2001). Similarly, overexpression of MMP-1
in oesophageal carcinoma (Yamashita et al, 2001) and MMP-12 in
patients with CRC (Yang et al, 2001) closely correlated with better
prognosis, whereas the occurrence of elevated levels of a 50-kDa
gelatinolytic MMP species (likely to represent MMP-1) in patients
with breast cancer corresponded to better survival (Remacle et al,
1998). Although these findings contradict our current under-
standing on the cancer-promoting activity of MMPs, these
enzymes have substrates other than typical structural matrix
proteins. For example, it has been suggested that the mechanism
by which endothelial cell proliferation and tumour angiogenesis is
inhibited is via the ability of MMP-7, -9, and -12 to convert
plasminogen in to angiostatin (Dong et al, 1997). This concept was
further supported by studies that demonstrated the ability of
MMP-9 to generate tumstatin (a potent angiogenesis inhibitor)
from type IV collagen (Hamano et al, 2003) and the MMP-
mediated formation of endostatin (Nilsson and Dabrosin, 2006). A
beneficial role for MMP-1 has also been observed in athero-
sclerosis, whereby the active digestion of interstitial fibrillar
collagen (types I, II, and III) by this enzyme affected cell
differentiation and impaired cell migration (Lemaitre et al,
2001). A second mechanism, by which MMPs might function as
inhibitors of tumour progression, is via their ability to cleave cell-
surface receptors. The proteolytic cleavage of the oestrogen
receptor b by MMP-26 was recently demonstrated by Savinov
et al (2006) and this correlated with longer survival in patients with
breast cancer. Finally, increased MMP activity has been shown to
disrupt or denature adhesion molecules such as E-cadherin,
thereby instigating tumour regression (Simian et al, 2006).
Confirmation of the protective effects of MMPs in cancer has
come from animal experiments where tumours that arise from
MMP-9 knockout (KO) mice were of a higher grade and displayed
increased aggressiveness (Coussens et al, 2000). Likewise, squa-
mous cell carcinoma induced in MMP-3 null mice grew more
rapidly than tumours in control animals (McCawley et al, 2004).
The authors proposed that MMP-3 plays a role in host defense
during tumorigenesis, a likely mechanism, given the impaired
immunity to bacterial infection in similar KO animals (Li et al,
2004). Increased incidence of skin tumours has been observed in
MMP-8-deficient mice. Interestingly, protection against tumour
development was restored when MMP-8-containing bone marrow
cells were transferred back into these animals (Balbin et al, 2003).
Other examples of the protective effect against tumour formation
have been observed in vivo after treatment with synthetic MMP
inhibitors (Coussens et al, 2002). Apart from the documented
musculoskeletal pain and inflammation these agents cause in
humans, there is evidence to suggest that they promote metastasis
(Kruger et al, 2001).
To our knowledge, this is the first report that supports the
hypothesis that a genetic variant in the MMP-1 promoter
(associated with enzyme overexpression) favours overall survival
in patients with CRC. Although the reason for this is unclear, host
and/or tumour-related mechanisms are likely. A limitation of our
study was that we did not confirm whether this polymorphism was
indeed functional. There is, however, ample supportive evidence
establishing the functionality of this polymorphism in both normal
stromal cells (Wyatt et al, 2002) and tumour cells, including
melanoma (Tower et al, 2003a) and breast cancer cells (Tower et al,
2003b). These studies confirmed that cells containing a 2G allele
displayed enhanced transcriptional activity compared to cells
harbouring the 1G allele. It was also noted that if MMP-1
transcriptional activity was not altered as a consequence of the
MMP-1 polymorphism, then expression of this enzyme was likely to
be differentially induced in response to cytokines and growth factors
(Rutter et al, 1998; Tower et al, 2002; Wyatt et al,2 0 0 2 ) .
Investigations are currently underway in our laboratory to address
this issue and to determine whether our observations are tumour-
specific, or applicable to other adenocarcinomas such as breast and
prostate. Finally, although our results may provide patients and
physicians with a more accurate estimation of prognosis compared
to methods currently available, they may also influence the timing
and choice of chemotherapy for patients suffering from CRC.
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